Применение канакинумаба при болезни Стилла взрослых
https://doi.org/10.14412/1995-4484-2018-35-40
Аннотация
Об авторе
Е. Л. НасоновРоссия
115522 Москва, Каширское шоссе, 34А;
кафедра ревматологии Института профессионального образования, 119991 Москва, ул. Трубецкая, 8, стр. 2
Список литературы
1. Still GF. On a form of chronic joint disease in children. Med Chir Trans. 1897;80:47-60. doi: 10.1177/095952879708000106
2. Bywaters EG. Still's disease in the adult. Ann Rheum Dis. 1971;30:121-33. doi: 10.1136/ard.30.2.121
3. McGonagle D, McDermott MF. A proposed classification of the immunological diseases. PLOS Med. 2006;3:e297. doi: 10.1371/journal.pmed.0030297
4. Peckham D, Scambler T, Savic S, McDermott MF. The burgeoning field of innate immune-mediated disease and autoinflammation. J Pathol. 2017;241:123-39. doi: 10.1002/path.4812
5. Nirmala N, Brachat A, Feist E, et al. Gene-expression analysis of adult-onset Still's disease and systemic juvenile idiopathic arthritis is consistent with a continuum of a single disease entity. Pediatr Rheumatol Online J. 2015;13:50. doi: 10.1186/s12969-015-0047-3
6. Efthimiou P, Moorthy LN, Mavragani CP, et al. Adult Onset Still's Disease and Autoinflammation. Int J Inflam. 2012;2012:964751. doi: 10.1155/2012/9647
7. Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still's disease. Nat Rev Rheumatol. 2018;14(10):603-18. doi: 10.1038/s41584-018-0081-x
8. Fautrel B. Adult-onset Still disease. Best Pract Res Clin Rheumatol. 2008;22:773-92. doi: 10.1016/j.berh.2008.08.006
9. Муравьев ЮВ, Насонов ЕЛ. Болезнь Стилла, развившаяся у взрослых. Научно-практическая ревматология. 2011;49(2):58-65. doi: 10.14412/1995-4484-2011-604
10. Gerfaud-Valentin M, Jamilloux Y, Iwaz J, Seve P. Adult-onset Still’s disease. Autoimmun Rev. 2014;13:708-22. doi: 10.1016/j.autrev.2014.01.058
11. Giacomelli R, Ruscitti P, Shoenfeld Y. A comprehensive review on adult onset Still's disease. J Autoimmun. 2018 Sep;93:24-36. doi: 10.1016/j.jaut.2018.07.0
12. Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still's disease. J Rheumatol. 1992;19:424-30.
13. Fautrel B, Zing E, Golmard JL, et al. Proposal for a new set of classification criteria for adult-onset Still disease. Medicine. 2002;81:194-200. doi: 10.1097/00005792-200205000-00003
14. Lebrun D, Mestrallet S, Dehoux M, et al. Validation of the Fautrel classification criteria for adult-onset Still's disease. Semin Arthritis Rheum. 2018;47:578-85. doi: 10.1016/j.semarthrit.2017.07.005
15. Mitrovic S, Fautrel B. New markers for adult-onset Still's disease. Joint Bone Spine. 2018;85:285-93. doi: 10.1016/j.jbspin.2017.05.011
16. Mavragani CP, Spyridakis EG, Koutsilieris M. Adult-Onset Still's Disease: From Pathophysiology to Targeted Therapies. Int J Inflam. 2012;2012:879020. doi: 10.1155/2012/879020
17. Maria AT, Le Quellec A, Jorgensen C, et al. Adult onset Still's disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions. Autoimmun Rev. 2014;13:1149-59. doi: 10.1016/j.autrev.2014.08.032
18. Govoni M, Bortoluzzi A, Rossi D, Modena V. How I treat patients with adult onset Still's disease in clinical practice. Autoimmun Rev. 2017 Oct;16(10):1016-23. doi: 10.1016/j.autrev.2017.07.017
19. Mimura T, Kondo Y, Ohta A, et al. Evidence-based clinical practice guideline for adult Still's disease. Mod Rheumatol. 2018;28(5):736-57. doi: 10.1080/14397595.2018
20. Ruscitti P, Giacomelli R. Pathogenesis of adult onset still's disease: current understanding and new insights. Expert Rev Clin Immunol. 2018;14(11):965-76. doi: 10.1080/1744666X.2018.15
21. Girard C, Rech J, Brown M, et al. Elevated serum levels of free interleukin-18 in adult-onset Still's disease. Rheumatology (Oxford). 2016;55(12):2237-47. doi: 10.1093/rheumatology/kew300
22. Inoue N, Shimizu M, Tsunoda S, et al. Cytokine profile in adultonset Still's disease: Comparison with systemic juvenile idiopathic arthritis. Clin Immunol. 2016;169:8-13. doi: 10.1016/j.clim.2016.05.010
23. Ichida H, Kawaguchi Y, Sugiura T, et al. Clinical manifestations of Adult-onset Still's disease presenting with erosive arthritis: Association with low levels of ferritin and Interleukin-18. Arthritis Care Res (Hoboken). 2014;66(4):642-6. doi: 10.1002/acr.22194
24. Zhou S, Qiao J, Bai J, et al. Biological therapy of traditional therapy-resistant adult-onset Still's disease: an evidence-based review. Ther Clin Risk Manag. 2018;14:167-71. doi: 10.2147/TCRM.S15
25. Ruscitti P, Ursini F, Cipriani P, et al. Biologic drugs in adult onset Still's disease: a systematic review and meta-analysis of observational studies. Expert Rev Clin Immunol. 2017;13(11):1089-97. doi: 10.1080/1744666X.2017.1375853
26. Gerfaud-Valentin M, Maucort-Boulch D, Hot A, et al. Adultonset Still disease: manifestations, treatments, outcome, and prognostic factors in 57 patients. Medicine. 2014;93:91-9. doi: 10.1097/MD.0000000000000021
27. Vitale A, Insalaco A, Sfriso P, et al. A snapshot on the on-label and off-label use of the interleukin-1 inhibitors in Italy among rheumatologists and pediatric rheumatologists: a nationwide multi-center retrospective observational study. Front Pharmacol. 2016;7:380. doi: 10.3389/fphar.2016.00380
28. Cipriani P, Ruscitti P, Carubbi F, et al. Tocilizumab for the treatment of adult-onset Still's disease: results from a case series. Clin Rheumatol. 2014;33:49-55. doi: 10.1007/s10067-013-2381-5
29. Ma Y, Wu M, Zhang X, et al. Efficacy and safety of tocilizumab with inhibition of interleukin-6 in adult-onset Still's disease: A meta-analysis. Mod Rheumatol. 2018;28(5):849-57. doi: 10.1080/14397595.2017.1416924
30. Kaneko Y, Kameda H, Ikeda K, et al. Tocilizumab in patients with adult-onset Still's disease refractory to glucocorticoid treatment: A randomised, double-blind, placebo-controlled phase III trial. Ann Rheum Dis. 2018 Oct 2. pii: annrheumdis-2018-213920. doi: 10.1136/annrheumdis-2018-213
31. Pouchot J, Sampalis JS, Beaudet F, et al. Adult Still's disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore). 1991;70:118-36. doi: 10.1097/00005792-199103000-00004
32. Ruscitti P, Cipriani P, Masedu F, et al. Adult onset Still's disease: evaluation of prognostic tools and validation of the systemic score, by analysis of 100 cases from three centers. BMC Med. 2016;14:194. doi: 10.1186/s12916-016-0738-8
33. Ruperto N, Quartier P, Wulffraat N, et al. A phase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum. 2012;64:557-67. doi: 10.1002/art.33342
34. Ruperto N, Brunner HI, Quartier P, et al. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367:2396-406. doi:10.1056/NEJMoa1205099
35. Ruperto N, Brunner HI, Quartier P, et al. Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials. Ann Rheum Dis. 2018 Sep 29. pii: annrheumdis-2018- 213150. doi: 10.1136/annrheumdis-2018-213150
36. Brunner HI, Ruperto N, Quartier P, et al. Efficacy and Safety of Canakinumab in Children with Systemic Juvenile Idiopathic Arthritis: Results from the Phase 3 Extension Study [abstract]. Arthritis Rheum. 2015;67 Suppl 10:Abstract Number: 2422.
37. Grom AA, Ilowite NT, Pascual V, et al. Paediatric Rheumatology International Trials Organisation and the Pediatric Rheumatology Collaborative Study Group. Rate and Clinical Presentation of Macrophage Activation Syndrome in Patients With Systemic Juvenile Idiopathic Arthritis Treated With Canakinumab. Arthritis Rheum. 2016;68(1):218-28. doi: 10.1002/art.39407
38. Brunner HI, Ruperto N, Quartier P, et al. Efficacy and Safety of Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis: Results from an Open-Label Long-Term Follow-up Study. Arthritis Rheum. 2016;68 Suppl 10. Number: 2374.
39. Brunner HI, Ruperto N, Quartier P, et al. Long-Term Efficacy and Safety of Canakinumab in Patients with Active Systemic Juvenile Idiopathic Arthritis (SJIA): Results from a PHASE III Extension Study. Arthritis Rheum. 2016;68 Suppl 10. Abstract Number: 3007.
40. Ruperto N, Brunner HI, Quartier P, et al.Treating To Target with Canakinumab in Patients with Active Systemic Juvenile Idiopathic Arthritis: Results from The Long-Term Extension The Phase III Pivotal Trial. Ann Rheum Dis. 2016;75:401-2. doi: 10.1136/annrheumdis-2016-eular.2658
41. Ruperto N, Brunner HI, Quartier P, et al, on behalf of PRINTO/PRCSG. Long-Term Efficacy and Safety of Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis (SJIA): 5-Year Follow-up of An Open-Label Trial. Ann Rheum Dis. 2016;75:265-6. doi: 10.1136/annrheumdis-2016- eular.3835
42. Horneff G, Peitz J, Kekow J, Foell D. Canakinumab for first line steroid-free treatment in a child with systemic-onset juvenile idiopathic arthritis. Scand J Rheumatol. 2017;46(6):500-1. doi: 10.1080/03009742.2017.1288827
43. Orrock JE, Ilowite NT. Canakinumab for the treatment of active systemic juvenile idiopathic arthritis. Expert Rev Clin Pharmacol. 2016;9(8):1015-24. doi: 10.1080/17512433.2016.1204910
44. Sun H, Van LM, Floch D, et al. Pharmacokinetics and pharmacodynamics of canakinumab in patients with systemic juvenile idiopathic arthritis. J Clin Pharmacol. 2016;56:1516-27. doi: 10.1002/jcph.754
45. Kontzias A, Efthimiou P. The use of Canakinumab, a novel IL-1beta long-acting inhibitor, in refractory adult-onset Still's disease. Semin Arthritis Rheum. 2012;42:201-5. doi: 10.1016/j.semarthrit.2012.03.004
46. Banse C, Vittecoq O, Benhamou Y, et al. Reactive macrophage activation syndrome possibly triggered by canakinumab in a patient with adult-onset Still's disease. Joint Bone Spine. 2013;80:653-5. doi: 10.1016/j.jbspin.2013.04.011
47. Eriksson P, Jacobs C, Soderkvist P. A patient with a phenotype of adult-onset Still disease, but a genotype typical of cryopyrin-associated periodic fever syndrome. J Rheumatol. 2013;40:1632-3. doi: 10.3899/jrheum.130325
48. Barsotti S, Neri R, Iacopetti V, et al.. Successful treatment of refractory adult-onset Still disease with canakinumab: A case report. J Clin Rheumatol. 2014;20:121. doi: 10.1097/rhu.00000000000000
49. Lo Gullo A, Caruso A, Pipitone N, et al. Canakinumab in a case of adult onset Still's disease: efficacy only on systemic manifestations. Joint Bone Spine. 2014;81:376-7. doi: 10.1016/j.jbspin.2013.12.011
50. Rossi-Semerano L, Fautrel B, Wendling D, et al. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: A nationwide survey. Orphanet J Rare Dis. 2015;10:19.
51. Colafrancesco S, Priori R, Valesini G, et al. Response to interleukin-1 inhibitors in 140 Italian patients with adult-onset Still's disease: A multicentre retrospective observational study. Front Pharmacol. 2017;8:369. doi: 10.3389/fphar.2017.00369
52. Feist E, Quartier P, Fautrel B, et al. Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups. Clin Exp Rheumatol. 2018;36:668-75.
53. Feist E, Quartier P, Fautrel B, et al. Efficacy and safety of canakinumab in patients with Still's disease: a pooled analysis of sjia data by age groups. Ann Rheum Dis. 2018;76(Suppl 2):395-6. doi: 10.1136/annrheumdis-2017-eular.1979
54. Sinha A, Patti R, Ambesh P, et al. Severe pulmonary hypertension due to adult-onset Still's disease. J Investig Med High Impact Case Rep. 2018;6:2324709618757260. doi: 10.1177/2324709618757260
55. Ugurlu S, Guzelant G, Yurttas B, et al. Canakinumab treatment in adult-onset Still's disease: case series. Ann Rheum Dis. 2018;76(Suppl 2):514. doi: 10.1136/annrheumdis-2018-eular.7187
56. Athanassiou P, Basdragianni D, Tzanavari A, et al. Adult Still's disease: successful treatment with canakinumab. Osteoporos Int. 2014;25:S424.
57. Galozzi P, Baggio C, Bindoli S, et al. Development and Role in Therapy of Canakinumab in Adult-Onset Still's Disease. Front Pharmacol. 2018 Sep 21;9:1074. doi: 10.3389/fphar.2018.01074
58. Junge G, Mason J, Feist E. Adult onset Still's disease-The evidence that anti-interleukin-1 treatment is effective and well-tolerated (a comprehensive literature review). Semin Arthritis Rheum. 2017;47(2):295-302. doi: 10.1016/j.semarthrit.2017.06.006
59. Brachat AH, Grom AA, Wulffraat N, et al. Pediatric Rheumatology International Trials Organization (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG). Early changes in gene expression and inflammatory proteins in systemic juvenile idiopathic arthritis patients on canakinumab therapy. Arthritis Res Ther. 2017;19(1):13. doi: 10.1186/s13075-016-1212
60. Colafrancesco S, Priori R, Valesini G, et al. Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study. Front Pharmacol. 2017 Jun 13;8:369. doi: 10.3389/fphar.2017.00369
61. Hong D, Yang Z, Han S, et al. Interleukin 1 inhibition with anakinra in adult-onset Still disease: A meta-analysis of its efficacy and safety. Drug Des Devel Ther. 2014;8:2345-57. doi: 10.2147/DDDT.S73428
Рецензия
Для цитирования:
Насонов Е.Л. Применение канакинумаба при болезни Стилла взрослых. Научно-практическая ревматология. 2018;56:35-40. https://doi.org/10.14412/1995-4484-2018-35-40
For citation:
Nasonov E.L. Therapy with canakinumab for adult-onset still's disease. Rheumatology Science and Practice. 2018;56:35-40. (In Russ.) https://doi.org/10.14412/1995-4484-2018-35-40